Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to use Sorafenib plus Docetaxel to evaluate pharmacodynamics (PD) in Patients with prostate cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Italian Trial in Medical Oncology
• Treatments: Docetaxel; Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• Patients with metastatic hormone refractory prostate cancer